November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Headed to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Viscous-dispersive OVD offers best of both worlds
October 15th 2004Kingston, PA-FDA study results show the safety and effectiveness of the investigational viscous-dispersive ophthalmic viscosurgical device (OVD) DisCoVisc (Alcon Laboratories) for use during cataract surgery and IOL implantation, said Harvey Reiser, MD.
Read More
What does the future hold for AMD management?
October 15th 2004Therapies for the management of age-related macular degeneration (AMD) have progressed rapidly in recent years. Ophthalmology Times convened a panel of cutting-edge retinal specialists from across the United States to discuss the latest in the diagnosis of AMD and to explore current practice patterns with pharmaceutical and surgical treatment options.
Read More
The FDA approval in mid-September of the Verisyse/Artisan phakic IOL [Advanced Medical Optics Inc. (AMO) and Ophtec USA] for use in patients with myopia could be the start of a revolution comparable to the advent of LASIK, according to Eric D. Donnenfeld, MD, FACS, one of the investigators who took part in clinical trials of the lens.
Read More
Interim results find phakic IOL useful for high hyperopia
October 1st 2004San Diego-The Artisan Hyperopia IOL (Ophtec BV) appears to be safe, effective, and stable for the treatment of high and extreme hyperopia, according to Edward E. Manche, MD, who reported the interim results of the FDA phase III clinical trial at the American Society of Cataract and Refractive Surgery annual meeting.
Read More
WaveLight earns FDA approval for further clinical studies
September 17th 2004The U.S. FDA has granted WaveLight Laser Technologie AG, an investigational device exemption that allows the company, based in Erlangen, Germany, to conduct additional clinical studies in the United States for its Allegretto Wave excimer laser system.
Read More
Intravenous agent safe, effective anti-angiogenic compound
September 15th 2004Fort Lauderdale, FL-Intravenous squalamine lactate being developed by Geneara Corp. shows promise as a safe and effective treatment for choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), according toresults of a phase I/II trial presented by Charles A. Garcia, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Iris-fixated lens effective for high myopia up to -20 D
September 1st 2004San Diego-The Artisan/Verisyse phakic IOL (Ophtec USA, AMO) fared well in preliminary analysis of data from one U.S. investigational center. It appears to be a safeand effective implant for use in patients with high myopia, according to Kerry Assil, MD, who spoke during the American Society of Cataract and Refractive Surgery annual meeting.
Read More
UVA cross-linking may stabilize cornea after refractive surgery
September 1st 2004San Diego-Regression after refractive surgery may be reduced by using ultraviolet A (UVA) cross-linking techniques to stabilize the cornea. The preliminary results of UVA cross-linking after refractive procedures demonstrated that regression stopped in the near term and appeared to be without adverse effects.
Read More
Refocus Group reports promising initial results
September 1st 2004Dallas-Refocus Group Inc., a medical device company engaged in the research and development of treatments for eye disorders, announced promising preliminary data from the company's ongoing phase II clinical trials for the treatment of presbyopia.
Read More
Drug delivery device effective in macular edema trial
August 15th 2004Baltimore-A dexamethasone posterior segment drug delivery system (Posurdex, Allergan), developed by Oculex Pharmaceu- ticals, performed well in a phase II trial in patients with macular edema, with a 700-?g dose achieving statistically significant results when compared with an observation-only control group, according to Julia A. Haller, MD.
Read More
Visual acuity benefit seen with SnET2 photodynamic therapy
August 1st 2004Fort Lauderdale, FL-The investigational drug tin ethyl etiopurpurin (SnET2) produced a visual acuity benefit and slowed the development of neovascular lesions in two phase III trials of SnET2 photodynamic therapy (PDT) (Miravant Medical Technologies) for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration, said Edgar L. Thomas, MD, Retina-Vitreous Associates, Los Angeles.
Read More
Visual acuity benefit seen with SnET2 photodynamic therapy
August 1st 2004Fort Lauderdale, FL-The investigational drug tin ethyl etiopurpurin (SnET2) produced a visual acuity benefit and slowed the development of neovascular lesions in two phase III trials of SnET2 photodynamic therapy (PDT) (Miravant Medical Technologies) for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration, said Edgar L. Thomas, MD, Retina-Vitreous Associates, Los Angeles.
Read More
Alcon gets 2nd review of potential AMD treatment
August 1st 2004Fort Worth, TX-Alcon Inc. has filed the second of three parts of its "rolling" new drug application for anecortave acetate for depot suspension (Retaane) 15 mg, an investigational treatment for patients with wet age-related macular degeneration (AMD).
Read More
Small interfering RNA targets VEGF for exudative AMD
July 1st 2004Miami-Treatment with small interfering RNA (siRNA) directed against vascular endothelial growth factor (VEGF) is showing promise as a new therapy for choroidal neovascularization (CNV), according to Michael J. Tolentino, MD, who spoke at Angiogenesis 2004.
Read More
Quinolone can combat 22 new pathogens, FDA says
July 1st 2004Fort Worth, TX-Alcon Inc. is adding 22 susceptible pathogens to its moxifloxacin HCl 0.5% ophthalmic solution (Vigamox) in vitro labeling. The additions, which the FDA approved in late April, include atypical mycobacteria and Propionibacterium acnes. Alcon said its fourth-generation fluoroquinolone eye drop now offers the broadest spectrum in the ophthalmic fluoroquinolone category.
Read More
FDA allows four firms to make generic solution
July 1st 2004Washington, DC-Four manufacturers of ocular products have received FDA approval to market ofloxacin ophthalmic solution 0.3%, a generic version of Allergan Inc.'s Ocuflox, for the treatment of certain strains of bacteria in conjunctivitis and corneal ulcers.
Read More